Objective. To develop algorithms for calculating the Rheumatic Diseases Comorbidity Index (RDCI), CharlsonDeyo Index (CDI) and Functional Comorbidity Index (FCI) from the Medical Dictionary for Regulatory Activities (MedDRA), and to assess how these MedDRA-derived indices predict clinical outcomes, utility and health resource utilization (HRU).
Introduction
Comorbidities in rheumatic and musculoskeletal diseases (RMDs) play an important role as they contribute to disability, need for healthcare and ultimately mortality [1, 2] . Comorbidities can co-occur by chance or can be related to (or enhanced by) the biopathology of the underlying rheumatic disease, the drug treatment or the patient's lifestyle.
Clinical cohorts and registers have come to play an important role in gathering evidence in effectiveness and safety of RA management, and increasingly guide clinical practice and policy decisions [3] . In this context, a standardized approach to assess adverse events and comorbidities is of the utmost importance. Medical Dictionary for Regulatory Activities (MedDRA) offers a five-level classification with nearly 70 000 terms to assess comorbidities and adverse events and is being increasingly used as an alternative to a three-level International Classification of Diseases-10 with approximately 17 000 items. The MedDRA is not only used by drug regulatory authorities, but also recommended to be used as the preferred dictionary for the coding of adverse events in European Biological Registries to ensure the homogeneity of data collection across registries [4, 5] . In rheumatology, not only the Norwegian Register of DMARDs (NOR-DMARD), but also other registries, such as the German (RABBIT), the British (BSRBR), the Portuguese (Reuma.pt) and the Spanish (BIOBADASER), use this classification system [610] .
MedDRA is used by regulatory authorities and in many clinical cohorts and registers worldwide to classify comorbidities and adverse events [11] . MedDRA is a hierarchical classification, encompassing 26 system organ classes (SOCs), corresponding to the highest level of the hierarchy. SOCs are followed by a high level group term (HLGT), a high level term (HLT), a preferred term (PT) and a lowest level term (LLT). For example, a myocardial infarction can be found in three SOCs at the highest level of hierarchy, namely, cardiac disorders, vascular disorders and injury, poisoning and procedural complications. In cardiac disorders, myocardial infarction is placed in the HLGT group coronary artery disorders, the HLT ischaemic coronary artery disorders with six corresponding PTs, namely acute myocardial infarction, coronary no-reflow phenomenon, myocardial infarction, myocardial stunning, post-procedural myocardial infarction and silent myocardial infarction. Finally, the six PTs are further split into 27 LLTs. In total, there are 69 019 terms in the lowest level of the hierarchy. While the detailed information on comorbid conditions can be essential to answer some specific research questions such as prevalence of certain rare adverse events, it is impractical when aiming to understand the overall role of comorbidities in outcome studies of a specific index disease. For such purposes, a composite comorbidity index that condenses the information on a series of co-morbidities into one single score is more useful.
Several comorbidity indices have been developed and validated for use in clinical studies [12, 13] . They differ in the type and number of comorbidities included, approaches to weigh the comorbidities into the index, the type of outcome they aim to predict and whether they use self-report or physician assessed comorbidities. The CharlsonDeyo Index (CDI) [14] and the Functional Comorbidity Index (FCI) [15] are among the most often used indices, the former being originally developed to predict mortality in cancer patients and the latter to predict functional status. Recently, a new and simple to compute index, the Rheumatic Disease Comorbidity Index (RDCI) [16] , has been proposed in addition to the existing indices for use in patients with RMDs. While all indices have been validated using information retrieved from clinical records, the RDCI can also be assessed by means of a patient reported questionnaire. Available evidence showed that the RDCI performs comparably well to existing indices in predicting functional status and mortality [17] . However, these data come from one single study. Moreover, the comparative performance of these indices in health care utilization and a broad range of outcomes assessing functioning has never been addressed.
Despite the fact that these comorbidity indices as well as disease classification systems such as the MedDRA or the International Classification of Diseases are widely used, as far as we know, so far no algorithm has been proposed for the computation of any comorbidity index from MedDRA. The objective of this study was to develop algorithms to calculate the RDCI, the CDI and the FCI from the MedDRA, and to assess how these MedDRA-derived indices predict physical function, physical and mental health, health utility, and health resource utilization (HRU).
Methods
Data from the NOR-DMARD were used. NOR-DMARD is a register of patients with inflammatory joint diseases treated with DMARDs, both conventional synthetic (csDMARDs) and biologic (bDMARDs). Five rheumatology departments covering a total of 1.7 million inhabitants (approximately one-third of the total population in Norway) have provided patient data since 2000 [18] . Each time a new DMARD has been started, study variables have been collected at treatment initiation, after 3, 6 and 12 months, and then yearly up to treatment termination. By 2012, the NOR-DMARD database comprised 6839 treatment courses in a total of 4126 patients with confirmed RA.
The NOR-DMARD has been approved by the Norwegian Data Inspectorate and the Regional Ethics Committee of Eastern Norway. Patients gave written informed consent before participation [19] . No additional approval was required for this study.
Comorbidity indices and their computation from MedDRA Table 1 describes the comorbidity indices considered for this study. The RDCI was developed as a self-reported questionnaire to understand the role of comorbidities on functioning in patients with RA, OA, SLE or FM [16] . It contains 11 conditions (currently present and/or present in the past) and the final score is derived by a sum score, with an extra weight for pulmonary and certain https://academic.oup.com/rheumatology cardiovascular conditions. The CDI was developed to predict mortality and comprises 22 currently present conditions, identified from clinical records or databases. Each condition is assigned a weight of 1, 3 or 6, resulting in a final score ranging from 0 to 36 [14] . The FCI aims to predict physical function by assessing the currently present comorbid conditions. The final score is the unweighted sum of 18 comorbidities (range 018) [15] .
To compute the comorbidity indices from MedDRA, all PTs (second lowest level, which was considered detailed enough for the purpose of the study) were manually linked to the corresponding conditions represented in the three comorbidity indices of interest by two researchers [A.B. (internist/rheumatologist) and S.R. (trainee in rheumatology)] based on consensus. After forward linkage, the conditions in the indices were also searched for in MedDRA to provide reassurance that no term was missed. As the aim was to develop an algorithm to be used by researchers in patients with inflammatory RMDs, 'Arthritis' was excluded from the FCI and 'CTD' from the CDI. Having been developed as a comorbidity index in RMDs, the RDCI did not include any index disease. Therefore, in this study the score for FCI ranged from 0 to 17 and for CDI from 0 to 35 (Table 1) . The link between each of the MedDRA terms and the diseases included in the different comorbidity indices can be found in supplementary Table S1 , available at Rheumatology online.
Outcomes
Physical function was measured by the modified HAQ (mHAQ) (03, higher scores are worse) [20] . HAQ was computed from the mHAQ [21] . Physical and mental function were measured by the physical and mental component summary (0100, the higher the better) of the Short Form 36 (SF-36) [22] . Additionally, a measure of health utility, the SF6D, was computed. SF6D is a societal preference-based single index measure for health, composed of six multi-level dimensions, derived from 11 questions of SF-36 items [23] . The SF-6D includes six health domains: pain, mental health, physical functioning, social functioning, role limitations and vitality; and has 18 000 health states. HRU not related to RA was computed from the number of hospitalizations in a department other than rheumatology in the past 3 months and the number of visits to an outpatient clinic other than rheumatology in the past 3 months. To deal with implausible outliers (>10 for hospitalizations and >20 outpatient visits in the past 3 months), two scenarios were developed: first (liberal) assuming a data entry mistake (10 was recoded with 1, 20 was recoded with 2, etc.), and second (conservative) recoding the outlier into missing. For analyses, HRU was converted into three dichotomous variables, hospitalization (yes/no), outpatient visit (yes/no) and a combined variable reflecting 'any HRU' (yes/no) in the past 3 months. Additionally, data on age, gender and DAS28 assessment at each visit were recorded.
Statistical methods
The predictive value for outcomes over time was assessed by linear and logistic generalized estimating equations (GEEs) with Gaussian family or binomial logit link function (as appropriate) and exchangeable correlation structure which assumes that the correlation between any pair of measurements on the same individual is the same. This technique is suitable for analysis of longitudinal data, and makes efficient use of all information longitudinally collected along all observations for each patient. Models were adjusted for age, gender and DAS28. As a sensitivity analyses, we have also explored the contribution of erosive disease and disease duration. Explanatory value of each of the comorbidity indices with respect to the outcomes was explored by comparing quasi-likelihood under the independence model criterion (QIC, which is a modification of Akaike information criteria for GEE) [24] . We first examined which of the three indices provided the best model fit: the lower the QIC, the better the model fit. Next, the improvement in the model fit was computed as the difference in QIC between the model not adjusted for comorbidities and the model adjusted for each of the three comorbidity indices, in order to capture the effect of adding the corresponding comorbidity index to the model: the higher the absolute value of the improvement, the better. Of note, absolute value of QIC cannot be meaningfully interpreted or compared across models with different outcomes. Analyses were done on complete cases per outcome, that is, the number of cases was the same across models within the same outcome. Analyses were performed with Stata v. 13 (StataCorp, College Station, TX, USA).
Results
The correspondence between the MedDRA codes and the categories of each index used for building the three comorbidity indices is presented in supplementary Table S1 , availabe at Rheumatology online. Data from 4126 patients with RA were analysed [72% female, mean (S.D.) age 56 (14) ( Table 2 ). The most common comorbidity was pulmonary disease (n = 386, 10%) in RDCI, followed by osteoporosis (n = 284, 7%) in FCI.
All three comorbidity indices improved the model fit compared with the model unadjusted for comorbidities, and overall, the differences in their performance in prediction of the selected outcomes were small to moderate. The FCI and RDCI consistently performed better than CDI on the clinical outcomes mHAQ (QIC improvement compared with model not adjusted for comorbidities À60 and À46 vs À24, respectively), HAQ (QIC improvement À84 and À72 vs À42), physical component summary (QIC improvement À48 744 and À49 394 vs À27 237) mental component summary (QIC improvement À28 586 and À22 682 vs À18 377) and SF6D (À4 and À3 vs À1). Results on HRU were mixed, and any HRU was best predicted by RDCI followed by CDI (Table 3 and Fig. 1; supplementary Fig. S1 , available at Rheumatology online). Further details of the GEE models are presented in supplementary Table S2 , available at Rheumatology online.
Finally, conservative and liberal scenarios for health care utilization did not yield different results (results from conservative scenario are not shown). Adding erosive disease or disease duration to the models did not affect the contribution of the comorbidity indices to the improvement of the model fit.
Discussion
In this study, the MedDRA coding was linked to the comorbidities represented in the RDCI, FCI and CDI in order to provide an algorithm to compute these often used comorbidity indices. Further, the RDCI, FCI and CDI performed similarly in predicting physical function, the physical and mental health, utility and HRU. Some differences were observed in how the three indices predicted outcomes of interest with especially better association for the RDCI and FCI when physical function or physical and mental health were the outcome. When any HRU (hospitalization or outpatient visit) was the outcome, FCI had inferior performance. It should be borne in mind that the CDI was developed to predict mortality and although RMDs result in higher mortality, they still have a higher impact on morbidity and therefore on the outcomes studied in these analyses.
MedDRA is a dynamic and regularly updated classification. To our knowledge, this study is the first one to offer an algorithm for computing several comorbidity indices for RMD field from this classification (the table of correspondence between all MedDRA codes and categories of each of the three comorbidity indices is presented in supplementary Table S1 , available at Rheumatology online). Further, few studies have explored the comparative performance of comorbidity indices, and the available studies looked at function and mortality as outcomes [15, 17, 25, 26] . Our results are consistent with the existing literature and show that FCI is best to predict physical function [15, 17] . To our knowledge, this is the first study in RA that included non-RA related HRU as an outcome. We observed that FCI was somewhat superior in predicting hospitalization, while CDI followed by the RDCI had best prediction value for an outpatient visit.
The current study does not reveal a strong preference for any of the outcome measures considered. While the choice of the comorbidity index is defined primarily by the purpose of the study (mental or physical functioning, mortality), type of data available (e.g. administrative records or self-report) and outcome of interest, previous studies have emphasized that the recently developed RDCI includes only a limited set of comorbidities (n = 11), which makes it simpler to compute from patient-reported data or to retrieve from chart review when MedDRA registration is not available for automatic computation [17] .
Our study has several limitations. First, we were not able to include mortality as an outcome; however, this outcome is one of the most studied and our results would be most likely only a validation of known evidence. Next, data on HRU was dichotomized, which did not allow studying costs of care received as an outcome, which would have been additionally informative. However, this is the first study that attempted to include this important outcome in a comparative study. Next, MedDRA classification codes were reviewed by two researchers with frequent discussions to reach a consensus, and therefore Cohen's k coefficient could not be calculated. In order to ensure correctness of the developed algorithm, after assigning each of the MedDRA terms to the conditions from the indices, the diseases included in each of the comorbidity indices linked to MedDRA codes were crosschecked for accuracy and consistency and were additionally searched in MedDRA terms. Only a few inconsistencies were detected and corrected with these additional checks, which supports the robustness of this method. Last but not least, validation of MedDRA-derived comorbidity indices by comparing with other ways of deriving comorbidities (e.g. from patient questionnaires) was not possible as relevant data were not available in NOR-DMARDs. This was thus a priori left beyond the scope of this paper, while it remains an important point for future research.
In summary, this study provided an algorithm to compute three commonly used comorbidity indices from the MedDRA classification. We have found that the RDCI, FCI and CDI perform comparably well in predicting physical function, physical and mental health, health utility and HRU, with the CDI having inferior performance on outcomes reflecting functioning and health compared with FCI and RDCI. All indices are suitable to be used in patients with RA, with RDCI being the shortest to compute and still performing as well as the others.
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